Aleena Banerji is a Rheumatology/Immunology physician affiliated with Harvard University. OpenAlex indexes 356 publications with 13,591 citations (h-index 60); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Allergy & Immunology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
100 Blossom Street
Cox 201
Boston, MA 021143117
Telephone
617-726-3850Registry record last updated 29 Jul 2014.
Clinical trials
- Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
Sponsor: Massachusetts General Hospital
- The Metabolomics of Anaphylaxis to Immunotherapy
Sponsor: Massachusetts General Hospital
- The Metabolomics of Anaphylaxis
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CSL BehringProgram year20255 payments
- BioCryst Pharmaceuticals, Inc.Program year20253 payments
- BioCryst US Sales Co., LLCProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Blood & clotting
38.1%Plasma Kallikrein Inhibitor16.7%Takhzyro100%Part D<11 patientsBradykinin B2 Receptor Antagonist14.8%Icatibant100%Part D<11 patients+ 1 more class in this area
Respiratory
35.7%Leukotriene Receptor Antagonist12.5%Montelukast Sodium100%Part D≥17 patientsCorticosteroid8.8%Fluticasone Propionate58%Arnuity Ellipta42%Part D<11 patients+ 3 more classes in this area
Dermatology
26.2%Interleukin-4 Receptor alpha Antagonist26.2%Dupixent Syringe79%Dupixent Pen21%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update
World Allergy Organization Journal
2022 - Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
New England Journal of Medicine
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Benjamin Ebert, MD
Harvard University
Mark Shrime, MD
Harvard University
Thoralf Sundt, MD
Harvard University
Dhaval Kolte, MBBS, PhD
Harvard University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”